Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema
<p>Abstract</p> <p>Up to now alpha 1-antitrypsin (AAT) augmentation therapy has been approved only for commercial use in selected adults with severe AAT deficiency-related pulmonary emphysema (i.e. PI*ZZ genotypes as well as combinations of Z, rare and null alleles expressing AAT s...
Main Authors: | de Serres Frederick, Lara Beatriz, Blanco Ignacio |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-04-01
|
Series: | Orphanet Journal of Rare Diseases |
Online Access: | http://www.ojrd.com/content/6/1/14 |
Similar Items
-
Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency
by: Gema Tirado-Conde, et al.
Published: (2008-02-01) -
The role of alpha-1-antitrypsin in the development of pulmonary emphysema
by: Dhami, Rajwinder Kaur
Published: (2009) -
The role of alpha-1-antitrypsin in the development of pulmonary emphysema
by: Dhami, Rajwinder Kaur
Published: (2009) -
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
by: Irina Petrache, et al.
Published: (2009-05-01) -
Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy
by: Juan Carlos Barros-Tizón, et al.
Published: (2012-04-01)